Atriva Therapeutics: a quantum leap in antiviral respiratory therapies
Atriva Therapeutics is developing a unique portfolio of broadly active and efficacious antiviral drugs based on MEK inhibitors, including its lead candidate ATR-002, which may revolutionize the treatment of influenza and other severe respiratory viral infections.
No comments yet.